What is Alaunos Therapeutics, Inc's earnings per share (EPS)?

Alaunos Therapeutics, Inc (TCRT) reported diluted earnings per share of $-2.20 for fiscal year 2025. This represents a 24.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Alaunos Therapeutics, Inc Financials

TCRT

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Alaunos Therapeutics, Inc (TCRT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 22 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.69x

For every $1 of reported earnings, Alaunos Therapeutics, Inc generates $0.69 in operating cash flow (-$2.9M OCF vs -$4.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5K

YoY-50.0%

Alaunos Therapeutics, Inc generated $5K in revenue in fiscal year 2025. This represents a decrease of 50.0% from the prior year.

EBITDA

-$4.2M

YoY+12.3%

Alaunos Therapeutics, Inc's EBITDA was -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.3% from the prior year.

Net Income

-$4.2M

YoY+10.8%

Alaunos Therapeutics, Inc reported -$4.2M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.

EPS (Diluted)

$-2.20

YoY+24.7%

Alaunos Therapeutics, Inc earned $-2.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 24.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$3.0M

YoY+40.3%

Alaunos Therapeutics, Inc generated -$3.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 40.3% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY+48.5%

5Y CAGR-59.4%

10Y CAGR-33.1%

Alaunos Therapeutics, Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 48.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-84500.0%

YoY-36380.0pp

Alaunos Therapeutics, Inc's operating margin was -84500.0% in fiscal year 2025, reflecting core business profitability. This is down 36380.0 percentage points from the prior year.

Net Margin

-83520.0%

YoY-36730.0pp

Alaunos Therapeutics, Inc's net profit margin was -83520.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 36730.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.4M

YoY+276.5%

5Y CAGR-51.9%

10Y CAGR-35.3%

Alaunos Therapeutics, Inc invested $1.4M in research and development in fiscal year 2025. This represents an increase of 276.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$98K

5Y CAGR-60.2%

10Y CAGR-13.4%

Alaunos Therapeutics, Inc invested $98K in capex in fiscal year 2025, funding long-term assets and infrastructure.

TCRT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5K-50.0%	$10K+100.0%	$5K-99.8%	$2.9M+634.2%	$398K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.4M+276.5%	$362K-97.8%	$16.3M-34.9%	$25.0M-49.6%	$49.6M-5.8%	$52.7M
SG&A Expenses	$2.9M-35.7%	$4.5M-63.5%	$12.2M-7.0%	$13.1M-52.3%	$27.6M-0.4%	$27.7M
Operating Income	-$4.2M+12.2%	-$4.8M+86.0%	-$34.3M+2.4%	-$35.1M+54.7%	-$77.5M+3.5%	-$80.4M
Interest Expense	N/A	$0-100.0%	$1.9M-39.1%	$3.2M+165.3%	$1.2M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.2M+10.8%	-$4.7M+86.7%	-$35.1M+6.9%	-$37.7M+52.1%	-$78.8M+1.5%	-$80.0M
EPS (Diluted)	$-2.20+24.7%	$-2.92+86.7%	$-21.97-741.8%	$-2.61-605.4%	$-0.37+2.6%	$-0.38

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0-100.0%	$2K	N/A	$0-100.0%	$4K+300.0%	$1K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$469K+153.5%	$185K-46.7%	$347K	N/A	$143K-20.6%	$180K+42.9%	$126K	N/A
SG&A Expenses	$718K-15.9%	$854K+14.3%	$747K	N/A	$1.0M+1.7%	$990K-38.8%	$1.6M	N/A
Operating Income	-$1.2M-14.2%	-$1.0M+4.9%	-$1.1M	N/A	-$1.1M+1.4%	-$1.2M+33.1%	-$1.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$0	$0	$0	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M-10.3%	-$1.1M+2.1%	-$1.1M	N/A	-$1.1M+0.2%	-$1.1M+32.9%	-$1.7M	N/A
EPS (Diluted)	$-0.55+12.7%	$-0.63+6.0%	$-0.67	N/A	$-0.70+1.4%	$-0.71+32.4%	$-1.05	N/A

TCRT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$2.8M-66.7%	$8.3M-87.3%	$64.9M-31.5%	$94.9M-35.2%	$146.3M
Current Assets	N/A	$2.8M-66.7%	$8.3M-84.6%	$53.8M-31.8%	$78.8M-39.6%	$130.6M
Cash & Equivalents	N/A	$1.1M-82.0%	$6.1M-84.5%	$39.1M-48.6%	$76.1M-33.9%	$115.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$692K-64.6%	$2.0M-92.6%	$26.4M-28.3%	$36.8M+64.6%	$22.4M
Current Liabilities	N/A	$692K-64.6%	$2.0M-91.9%	$24.2M+50.7%	$16.0M-12.7%	$18.4M
Long-Term Debt	N/A	$0	$0	$0-100.0%	$16.3M	$0
Total Equity	N/A	$2.1M-67.3%	$6.3M-83.6%	$38.6M-33.6%	$58.1M-53.2%	$124.0M
Retained Earnings	N/A	-$920.4M-0.5%	-$915.8M-4.0%	-$880.6M-4.5%	-$842.9M-10.3%	-$764.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$3.7M-21.4%	$4.7M+123.3%	$2.1M-23.0%	$2.8M-22.4%	$3.5M-24.1%	$4.7M-22.5%	$6.0M-26.9%	$8.3M
Current Assets	$2.7M-28.2%	$3.7M+250.3%	$1.1M-61.3%	$2.8M-22.4%	$3.5M-24.1%	$4.7M-22.5%	$6.0M-26.9%	$8.3M
Cash & Equivalents	$1.9M-32.7%	$2.9M+802.5%	$319K-70.8%	$1.1M-35.2%	$1.7M-31.7%	$2.5M-40.6%	$4.1M-31.6%	$6.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$921K-14.2%	$1.1M+1.1%	$1.1M+53.5%	$692K-16.2%	$826K-8.9%	$907K-26.9%	$1.2M-36.6%	$2.0M
Current Liabilities	$921K-14.2%	$1.1M+1.1%	$1.1M+53.5%	$692K-16.2%	$826K-8.9%	$907K-26.9%	$1.2M-36.6%	$2.0M
Long-Term Debt	N/A	N/A	N/A	$0	N/A	N/A	$0	$0
Total Equity	$2.8M-23.4%	$3.7M+246.0%	$1.1M-48.7%	$2.1M-24.3%	$2.7M-27.8%	$3.8M-21.4%	$4.8M-23.9%	$6.3M
Retained Earnings	-$923.7M-0.1%	-$922.6M-0.1%	-$921.5M-0.1%	-$920.4M-0.1%	-$919.7M-0.1%	-$918.6M0.0%	-$918.9M-0.3%	-$915.8M

TCRT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.9M+42.3%	-$5.0M+83.5%	-$30.1M-3.1%	-$29.2M+52.4%	-$61.5M-7.8%	-$57.0M
Capital Expenditures	$98K	$0-100.0%	$197K-8.8%	$216K-93.5%	$3.3M-66.0%	$9.8M
Free Cash Flow	-$3.0M+40.3%	-$5.0M+83.6%	-$30.3M-3.0%	-$29.4M+54.5%	-$64.8M+3.0%	-$66.8M
Investing Cash Flow	-$98K	$0-100.0%	$1.3M+797.4%	-$193K+94.2%	-$3.3M+66.0%	-$9.8M
Financing Cash Flow	$3.3M	$0+100.0%	-$18.1M-384.9%	$6.4M-75.3%	$25.8M-74.8%	$102.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0-100.0%	$45K	$0	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$844K-20.4%	-$701K+9.2%	-$772K-30.4%	-$592K+24.2%	-$781K+53.5%	-$1.7M+12.3%	-$1.9M+74.0%	-$7.4M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0	$0	$0
Free Cash Flow	N/A	N/A	N/A	-$592K+24.2%	-$781K+53.5%	-$1.7M+12.3%	-$1.9M+74.0%	-$7.4M
Investing Cash Flow	N/A	N/A	N/A	$0	$0	$0	$0-100.0%	$1.5M
Financing Cash Flow	$0	N/A	N/A	$0	$0	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0

TCRT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-84500.0%-36380.0pp	-48120.0%+637220.0pp	-685340.0%-684138.6pp	-1201.4%+18283.3pp	-19484.7%	N/A
Net Margin	-83520.0%-36730.0pp	-46790.0%+656010.0pp	-702800.0%-701508.8pp	-1291.2%+18495.4pp	-19786.7%	N/A
Return on Equity	N/A	-226.8%+330.4pp	-557.2%-459.3pp	-97.9%+37.8pp	-135.6%-71.1pp	-64.5%
Return on Assets	N/A	-169.8%+255.4pp	-425.3%-367.2pp	-58.1%+24.9pp	-83.0%-28.4pp	-54.6%
Current Ratio	N/A	3.98-0.2	4.22+2.0	2.23-2.7	4.91-2.2	7.11
Debt-to-Equity	N/A	0.000.0	0.000.0	0.00-0.3	0.28+0.3	0.00
FCF Margin	-59340.0%-9630.0pp	-49710.0%+557070.0pp	-606780.0%-605772.2pp	-1007.8%+15271.4pp	-16279.2%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-54600.0%	N/A	N/A	-29150.0%+145050.0pp	-174200.0%	N/A
Net Margin	N/A	N/A	-53650.0%	N/A	N/A	-28225.0%+139975.0pp	-168200.0%	N/A
Return on Equity	-41.3%-12.6pp	-28.7%+72.7pp	-101.4%	N/A	-41.4%-11.4pp	-29.9%+5.1pp	-35.1%	N/A
Return on Assets	-31.1%-8.9pp	-22.2%+28.4pp	-50.6%	N/A	-31.8%-7.6pp	-24.1%+3.7pp	-27.9%	N/A
Current Ratio	2.92-0.6	3.48+2.5	1.00-3.0	3.98-0.3	4.30-0.9	5.16+0.3	4.87+0.6	4.22
Debt-to-Equity	0.33+0.0	0.29-0.7	1.00+1.0	0.00-0.3	0.30+0.1	0.24+0.2	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	-42025.0%+149675.0pp	-191700.0%	N/A

Similar Companies

Aptevo Therapeutics Inc APVO

$4.9M

Aditxt Inc ADTX

$411K

GRI Bio GRI

$3.4M

Xenetic Biosciences Inc XBIO

$6.9M

Clearmind Medici CMND

$2.6M

Frequently Asked Questions

What is Alaunos Therapeutics, Inc's annual revenue?

Alaunos Therapeutics, Inc (TCRT) reported $5K in total revenue for fiscal year 2025. This represents a -50.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alaunos Therapeutics, Inc's revenue growing?

Alaunos Therapeutics, Inc (TCRT) revenue declined by 50% year-over-year, from $10K to $5K in fiscal year 2025.

Is Alaunos Therapeutics, Inc profitable?

No, Alaunos Therapeutics, Inc (TCRT) reported a net income of -$4.2M in fiscal year 2025, with a net profit margin of -83520.0%.

What is Alaunos Therapeutics, Inc's EBITDA?

Alaunos Therapeutics, Inc (TCRT) had EBITDA of -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Alaunos Therapeutics, Inc's operating margin?

Alaunos Therapeutics, Inc (TCRT) had an operating margin of -84500.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Alaunos Therapeutics, Inc's net profit margin?

Alaunos Therapeutics, Inc (TCRT) had a net profit margin of -83520.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Alaunos Therapeutics, Inc's free cash flow?

Alaunos Therapeutics, Inc (TCRT) generated -$3.0M in free cash flow during fiscal year 2025. This represents a 40.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alaunos Therapeutics, Inc's operating cash flow?

Alaunos Therapeutics, Inc (TCRT) generated -$2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Alaunos Therapeutics, Inc's capital expenditures?

Alaunos Therapeutics, Inc (TCRT) invested $98K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Alaunos Therapeutics, Inc spend on research and development?

Alaunos Therapeutics, Inc (TCRT) invested $1.4M in research and development during fiscal year 2025.

How many shares does Alaunos Therapeutics, Inc have outstanding?

Alaunos Therapeutics, Inc (TCRT) had 2M shares outstanding as of fiscal year 2025.

Are Alaunos Therapeutics, Inc's earnings high quality?

Alaunos Therapeutics, Inc (TCRT) has an earnings quality ratio of 0.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.